Obesity is a metabolic disease that affects all ages; it is considered life-threatening condition as it leads to fatal complications such as; cardiovascular diseases and diabetes. The therapeutic options include; life-style modifications, pharmacotherapy intervention, and surgical intervention. Bariatric surgery (BS) is considered as the most effective option among the others for its rapid weight loss, maintaining the lost mass, and improving the quality of life of the patients. Nevertheless, BS leads to severe changes in the bioavailability of medications, especially for chronic diseases, which may reach to limit where the patient's life endangers. Recently, pharmaceutical formulations had developed several methods to improve the drug bioavailability of drugs though the implying of nanotechnology. Nonotechnology is responsible for reducing the size of the drugs to the nano range (<1000 nm), which increase the drug surface area, dissolution, absorption, and, most importantly, the bioavailability of these drugs. It is believed that BS malabsorption and drugs bioavailability problems can be solved using nanotechnology for its advantages in overcoming BS complications.
Keywords: AGB, Adjustable Gastric band; ASMBS, American Society for Metabolic and Bariatric Surgery; Absorption; BS, Bariatric Surgery; Bariatric surgery; Bioavailability; CFR, Code of Federal Regulations; DDS, Drug Delivery System; FDA, Food and Drug Administration; GIT, Gastrointestinal Tract; GRS, Generally Recognized as Safe; ISCRPE, improved supercritical reverse phase evaporation; JIB, Jejunoileal bypass; LAG, Laparoscopic Sleeve Gastrectomy; MBI, Body Mass Index; MIC, Minimum Inhibitory Concentration; Nanotechnology; RYGB, Roux-en-Y gastric bypass; SCF, supercritical fluid; SNEDDS, selfnanoemulsifying drug delivery system; T2DM, Type 2 Diabetes Mellitus; VA, veteran affairs; WHO, World health organization.
© 2020 The Authors.